Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2001; 39(1): 63-65DOI: 10.1055/s-2001-10703 Leitlinien der DGVS © Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York Extraintestinale Manifestationen S. Schreiber Kiel Recommend Article Abstract Buy Article Full Text References Literatur 1 Ljunhall S, Ljunggren Ö. Inflammatory bowel disease and osteoporosis. Ital J Gastroenterol Hepatol. 1999; 31 103-109 2 Jahnsen J, Falch J A, Aadland E. et al . Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: A population based study. GUT. 1997; 40 313-331 (II a) 3 Sorensen H T, Fonager K M. Myocarditis and inflammatory bowel disease. A 16 year Danish nationwide cohort study. Dan Med Bull. 1997; 44 442-444 (III) 4 Shetty K, Rybicki L, Brzezinski A. et al . The risk for cancer or dysplasia in ulcerative colitis with primary sclerosing cholangitis. Am J Gastroenterol. 1999; 94 1643-1649 (III) 5 Broome U, Lofberg R, Veress B. et al . Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology. 1995; 22 1404-1408 (III) 6 Marchesa P, Lashner B A, Lavery I C. et al . The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997; 92 1285-1288 (III) 7 Greenstein A J, Sachar D B, Panday A K. et al . Amyloidosis and inflammatory bowel disease. A 50 year experience with 25 patients. Medicine. 1992; 71 261-270 (III) 8 Mielants H, Veys E M. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol. 1985; 12 287-293 (II b) 9 Rampton D S, Sladen G E. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981; 57 297-299 (III) 10 Secchi A G, De Rosa C, Pivetti-Pezzi P. et al . Open non-controlled multicenter long-term trial of ciclosporin in endogenous non-infectious uveitis. Ophthalmologica. 1991; 202 217-224 (II b) 11 Leuschner M, Maier K P, Schlichting J. et al . Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology. 1999; 117 918-925 (I b) 12 Stiehl L, Walker S, Rudolph G. et al . Effect of ursodeoxycolic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo controlled study period. J Hepatol. 1994; 20 57-64 (I b) 13 Sandborn W J, Wiesner R H, Tremaine W J. et al . Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporine. Gut. 1993; 34 242-246 (I b) 14 Larusso N F, Wiesner R H, Ludwig J. et al . Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology. 1988; 95 1036-1042 (I b) 15 Beuers U, Wiedmann K H, Kleber G. et al . Therapy of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Consensus of the German Society of Digestive System and Metabolic Diseases. Z Gastroenterol. 1997; 35 1041-1049 16 Bennett M L, Jackson J M, Jorizzo J L. et al . Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000; 79 37-46 (III) 17 Thomas P D, Keat A C, Forbes A. et al . Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy. Eur J Gastroenterol Hepatol. 1999; 11 1001-1005 (III)
